Human transferrin is a single-chain bilobal protein with each of the two similar but not identical lobes in turn composed of two domains. Each lobe may assume one of two stable structural conformations, open or closed, determined by a rigid rotation of the domains with respect to each other. In solution, the transformation of a lobe between open and closed conformations is associated with the release or binding of an Fe(III) ion. The results of the present study indicate that encapsulation of transferrin within a porous sol-gel matrix allows for a dramatic expansion, to days or weeks, of this interconversion time period, thus providing an opportunity to probe heretofore inaccessible transient intermediates. Sol-gel-encapsulated iron-free transferrin samples are prepared by using two protocols. In the first protocol, the equilibrium form of apotransferrin is encapsulated in the sol-gel matrix, whereas in the second protocol holotransferrin is first encapsulated and then iron is removed from the protein. Results of kinetic and spectroscopic studies allow for distinguishing between two models for iron binding. In the first, iron is assumed to bind to amino acid ligands of one domain, inducing a rigid rotation of the second domain to effect closure of the interdomain cleft. In the second, iron undertakes a conformational search among the thermally accessible states of the lobe, ''choosing'' the state which most nearly approximates the stable closed state when iron is bound. Our experimental results support the second mechanism.
T
ransferrins are iron-binding proteins that function in the transport of iron among cells that are absorbing, secreting, or in need of this essential element. Serum transferrin is composed of two similar but nonidentical globular lobes, with each lobe divided into two domains that consist of ␤-sheets overlaid with ␣-helices (1-3). Each lobe houses an Fe(III)-binding site in a cleft between its domains (4, 5) .
Domain motions are central to a variety of protein functions. For apotransferrin, the two domains of each lobe are, on average, in an open jaw conformation. When iron is bound, the domains close to surround the metal with their ligands. A phenolate-to-iron charge transfer transition at 465 nm arising from the binding of iron to two tyrosine ligands is responsible for the characteristic salmon-pink color of ironbearing lobes of transferrin (6) . Conversely, exposure of solution-phase holotransferrin to an iron-sequestering buffer at pH Ͻ5.0 results in the release of iron, loss of color, and return to the equilibrium open conformation of the iron-free lobe (7) . Molecular events that take place when iron is released or taken up are not easily probed in solution because the rate for conformational changes is likely to be much faster than the rate for iron diffusion or for the stochastic iron-release process (8) .
Sol-gel encapsulation of proteins (9-11) offers a possible means of overcoming the limitations described above. Sol-gelencapsulated proteins have been shown to retain reactivity with respect to uptake and release of substrates (9, (12) (13) (14) (15) (16) (17) . Although the sol-gel matrix prevents the loss of the encapsulated protein, its small pores allow nearly free diffusion of solvent and substrate molecules between the bathing solution and the encapsulated protein. Studies on hemoglobin and myoglobins encapsulated in tetramethyl orthosilicate (TMOS)-derived sol-gels reveal that the sol-gel matrix can limit protein conformational changes subsequent to the addition or the removal of ligands (18) (19) (20) (21) (22) . Large amplitude motions associated with the open-closed transitions of transferrin are, therefore, likely to be vulnerable to time-scale modulation by sol-gel matrix. Furthermore, by using three different sol-gel preparative protocols, it is possible to alter the physical and chemical properties of sol-gel matrices, thereby conferring varying degrees of conformational constraint on the encapsulated proteins (22) (23) (24) .
In the present study, equilibrium populations of apotransferrin are encapsulated from apotransferrin prepared in solution. Nonequilibrium populations are generated by first encapsulating an equilibrium population of iron-saturated (holo) transferrin. Iron is then removed from the encapsulated transferrin, thus generating an encapsulated iron-free form of the transferrin. The encapsulated iron-free transferrin prepared by means of the second method is referred to as apo*transferrin to differentiate it from samples of the encapsulated apotransferrin. The extent to which the sol-gel allows for relaxation after the release of iron will determine the extent to which the resulting apo*transferrin retains the closed conformation of the initially encapsulated holotransferrin or adopts the relaxed open conformation of the equilibrium apotransferrin. Experience with myoglobin and hemoglobin showed that sol-gels that confer differing degrees of conformational constraint upon the encapsulated protein can be prepared (22, 23) . Thus, it was anticipated that iron-free transferrin populations with conformations ranging from fully open to nearly closed could be prepared and compared with respect to iron uptake.
Protocols for the Preparation of Sol-Gel-Encapsulated Transferrins.
Apotransferrin and holotransferrin were encapsulated in porous sol-gels by using three different preparative protocols for the sol-gel derived from a method for protein encapsulation (9) . In each case, the protein solution was mixed with appropriate sol-gel precursors in a 10-mm diameter optical quality NMR tube (Wilmad, Buena, NY). The tube was then spun rapidly in an NMR tube spinner until the sol-gel had formed as a thin (Ͻ0.1 mm) layer lining the bottom one-fifth of the tube. After a short aging period, sufficient buffer was then introduced into the tube so as to have the sample completely immersed in an excess of buffer. Protocol 1. Tetramethyl orthosilicate (TMOS) was hydrolyzed by sonicating a mixture of 1.0 ml of TMOS (Aldrich), 0.050 ml of deionized water, and 0.040 ml of 2 mM acetic acid in an ice bath for 30 min to yield a clear solution. A mixture of 0.2 ml of 0.25 mM stock solution of protein, 0.14 ml of 50 mM Tris buffer, pH 7.5, and 0.060 ml of the hydrolyzed TMOS stock solution was then spun in a 10-mm-diameter NMR tube until a clear, well formed glassy layer was formed, normally within 30 min. Preparations were then immersed in 50 mM Tris buffer, pH 7.5, at 4°C. Samples so prepared were designated H for holotransferrin and A for apotransferrin with a subscript 1 for the protocol of their preparation, followed by an a or b to distinguish different samples; e.g., H 1a and H 1b for encapsulated holotransferrins or A 1a and A 1b for apotransferrins. A starred designation (A* 1a ) indicates apotransferrin derived from encapsulated H 1a .
Protocol 2. Two-tenths of a milliliter of protein, 0.127 ml of Tris buffer, 0.013 ml of polyethylene glycol (PEG 400, Sigma), and 0.060 ml of hydrolyzed TMOS were mixed for spinning; addition of PEG minimized the shrinkage of the gel that often occurs with aging (26, 27) . Samples so prepared were designated H 2 and A 2 , consistent with the description for Protocol 1 samples.
Protocol 3. Two-tenths of a milliliter of protein solution, 0.127 ml of 50 mM Tris buffer, pH 7.5, 0.0095 ml of PEG 400, 0.0032 ml of glycerol, and 0.060 ml of hydrolyzed TMOS were mixed. Samples so prepared were designated H 3 and A 3 , as above.
UV͞Visible Spectroscopy. The loss or gain of iron bound by transferrin was monitored by using the characteristic 465-nm ligand-to-metal charge-transfer band of iron-transferrin recorded with a Perkin-Elmer UV͞VIS Lambda 3B spectrophotometer. Sample tubes were positioned in a standard cell holder. Reference spectra were obtained from encapsulated holotransferrin or apotransferrin.
EPR Studies. EPR spectroscopy is sensitive to the presence of high-spin Fe(III) and is, therefore, used in the present study to detect any optically invisible irons remaining coordinated to transferrin samples that have been subjected to the iron release protocol. Protocol 1 was used to prepare holotransferrin and apotransferrin samples at 0.25 mM concentrations in quartz EPR tubes (Wilmad). To ensure efficient solvent exchange, it was necessary to prepare the samples as thin films by using a removable Teflon rod to mold a thin layer of the protein containing sol-gel within the EPR tubes because their narrow bores precluded generation of the thin sol-gel layer by the spinning method. Protocols described below for the removal and uptake of iron were applied. EPR spectra of the sol-gel thin films at 100K were obtained with a Bruker 200D͞ESP 300 spectrometer. Experimental parameters were microwave power, 10 mw; microwave frequency, 9.29-9.45 GHz; and modulation amplitude, 10 G.
Fluorescence Spectroscopy. Front-face fluorescence emission spectra of sol-gel-encapsulated transferrins at ambient temperature were obtained with a Shimadzu Model RF-5301 PC spectrofluorometer and an excitation wavelength of 280 nm. Other than intensity changes, probably resulting from sensitivity to sample positioning in front-face spectroscopy, there were no noticeable differences in the fluorescence spectrum when the excitation was changed to 290 nm. Peak positions were determined visually and numerically, the latter with PEAKFIT V.4.0.
Results
Iron Uptake for Sol-Gel-Encapsulated Apotransferrin. Iron uptake occurred over a period of days and weeks for sol-gel-encapsulated apotransferrin using the three different preparative protocols. A representative series of absorption spectra showing the progressive but slow increase in the intensity of the 465-nm band for sample A 2 is shown in Fig. 1A . Plots of iron uptake by encapsulated apotransferrin as a function of time are shown in Fig. 1B . Rates of iron uptake are similar for samples A 2 and A 3 but are substantially lower for sample A 1 (Ͻ15% uptake after 50 days).
Iron Release from Sol-Gel-Encapsulated Holotransferrins: Production of Encapsulated Apo*transferrin. The progress of iron release at pH 4.5 for samples H 1 , H 2 , and H 3 is shown in Fig. 2 . In all samples, Ϸ40% of the iron is released within a few minutes, and at least 70% is lost within a few hours, with the last 20-30% lost slowly over tens of hours.
Iron Uptake for Sol-Gel-Encapsulated Apo*transferrin. Intensity of the 465-nm band upon addition of Fe(NTA) 2 to sample A 2 * increases progressively until saturation of transferrin is achieved at about 100 h (Fig. 3 ). Iron uptake with respect to time for samples A 1 *, A 2 *, and A 3 * requires hours to days, rather than hours to weeks as in apotransferrin prepared before encapsulation, to approach completion. Uptake of iron levels off at a point very close to 50% saturation, which is suggestive of rebinding to only one lobe. Uptake is fastest for A 1 *, followed by A 3 *; it is slowest for A 2 *, the reverse of what is found for apotransferrin prepared before encapsulation (Fig. 1B) .
EPR Spectra of Sol-Gel-Encapsulated Transferrin. Fig. 4 shows the EPR spectra of encapsulated transferrin samples prepared by using Protocol 1. Spectra A-C and their signal intensities are all consistent with a substantial population of holotransferrin. Spectrum A is from encapsulated holotransferrin, whereas Spectrum B is from encapsulated holotransferrin sample exposed to an iron-sequestering buffer for an insufficient period to achieve full loss of iron. Spectrum C is from an encapsulated sample that was exposed to repeated changes of the iron-sequestering buffer for 2 days, resulting in a complete loss of color, followed by exposure to Fe(NTA) as described for iron uptake, with color returning. Samples A-C all had the characteristic pink color associated with holotransferrin. Sample D, with a negligible EPR signal, is derived from encapsulated holotransferrins that were repeatedly flushed and rendered colorless with the iron-sequestering buffer over a 2-day period.
The results demonstrate the absence of transferrin-bound iron that is optically and EPR silent [nonspecifically bound high-spin Fe(III) characteristically gives a signal centered near gЈ ϭ 4.3]. In all cases examined, there is a clear correlation between the intensity of the 465-nm transition (which is responsible for the pink color of holotransferrin) and the intensity of the EPR signal originating from protein-coordinated iron. This result justifies the use of the 465-nm band as an indicator of iron binding to transferrin in solution and sol-gel alike. Furthermore, the iron removal procedure eliminates EPR-detectable Fe(III), indicating the completeness of removal because released Fe(III) is expected to yield a signal.
Characterization of Sol-Gel-Encapsulated Transferrin by UV-Visible
Spectroscopy. Sol-gel samples prepared by the three different protocols were transparent, thin, and uniform. UV-visible absorption spectra of the encapsulated samples were virtually identical to those of the corresponding solution-phase samples. Absorption spectra are, therefore, consistent with preservation of native structures, although it is not clear how sensitive absorption spectra are to conformational perturbations.
Fluorescence Spectra from Sol-Gel-Encapsulated Holotransferrins.
To evaluate the significance of the kinetic differences among the encapsulated samples, it is essential to establish that the encapsulation processes have not significantly altered the conformation of the transferrin. It is also important to determine whether the kinetically distinct populations described above have spectroscopic signatures that might provide insight into protocol-specific differences in iron uptake. These two issues are addressed in the present work primarily by using tryptophan fluorescence from transferrin excited at 280 nm. This fluorescence, arising almost entirely from the tryptophan residues, is sensitive both to iron binding and to protein unfolding (28-30) and so may serve as a conformational probe of sol-gel-trapped iron-binding intermediates. Fig. 5A shows the 280-nm excited fluorescence spectra of encapsulated holotransferrin under several environmental conditions. The spectrum of encapsulated holotransferrin at pH 7.5 (trace a) is virtually identical to that obtained from a solution phase sample at that same pH, indicating the absence of disturbance by the preparative protocol. A summary of fluorescence peak positions (accurate to within Ϯ1 nm) for solution and sol-gel phase apotransferrin and holotransferrin is given in Table 1 .
Spectrum b in Fig. 5A shows the spectrum of an encapsulated holotransferrin sample exposed to 65°C and then allowed to cool; its peak shows little change from spectrum b. Significant but incomplete shifting toward the spectrum of the colorless, unfolded state obtained with 6 M guanidine⅐HCl (GuHCl) occurs for the sample heated at 100°C (spectrum c) and is also accompanied by a loss of color. In solution, complete unfolding (evidenced by the fluorescence spectrum) occurs upon heating to 60-70°C. Spectrum d indicates that the reported (29) fluorescence spectrum of the unfolded state of transferrin induced by guanidine can also be generated for the sol-gel-encapsulated colorless sample in 6 M GuHCl. All samples used to generate spectra a-f were prepared by using Protocol 2 (H 2). Spectrum a is from H2 bathed with aqueous buffer at pH 7.5 under ambient temperature; spectrum s is from an H 2 sample in a pH 7.5 bathing buffer heated for 1 h at 65°C and then returned to ambient temperature; spectrum c is from sample b heated for an additional hour at 100°C before cooling and acquisition; spectrum d is from an H 2 sample in which the pH 7.5 bathing buffer was replaced with 6 M GuHCl; spectrum e is from the sample used to generate spectrum d several hours after the GuHCl was replaced with 100% glycerol. (B) Fluorescence emission spectra of equilibrium and nonequilibrium forms of apotransferrin excited at 280 nm. Spectrum a is from apotransferrin in solution at pH 7.5; spectrum b is from sol-gel-encapsulated apotransferrin (A 2) at pH 7.5; spectrum c, shown for comparison, is from an H2 sample at pH 7.5; spectrum d is from an apo* transferrin sample (A1*) at pH 7.5 prepared from an encapsulated holotransferrin sample (H 1); spectrum e is from sample d in 6 M GuHCl.
Spectrum e is from sample d, with glycerol replacing the bathing buffer; its peak is almost restored to that of spectrum a.
The encapsulated sample that showed some degree of unfolding after heating to 100°C showed no change in its redshifted fluorescence even after several hours at ambient or cooler temperatures. Similarly, the GuHCl unfolded sample of encapsulated holotransferrin showed no change in the redshifted peak position at 353 nm when it is washed and the bathing buffer is replaced with denaturant-free pH 7.5 buffer. To test whether the sol-gel matrix stabilizes unfolded and partially unfolded conformations of transferrin, the bathing buffer in these partially and fully unfolded samples was replaced with pure glycerol to induce refolding. The fluorescence peak position of the samples showed a progressive blue shift over a period of several hours. Glycerol-induced spectra of chemically or thermally unfolded transferrin samples displayed peak positions approaching that of native apotransferrin. Replacement of glycerol with pH 7.5 buffer resulted in the progressive shifting of the fluorescence peak back to that of the unfolded protein (Ϸ353 nm) over a period of 1-2 days.
The extent of the blue-shifting of the spectrum in the presence of glycerol suggests that the sample had substantially refolded. However, the return to the ''fully unfolded'' spectra upon removing the renaturants suggests that the gel limits the degree of refolding. One possibility (31) is that segments of unfolded protein are trapped in pores permeating the sol-gel matrix, thereby constraining refolding. If so, loosening the pores or increasing the mobility of the segments should increase the degree of refolding. Thus, heating at temperatures sufficiently to enhance both conformational mobility and loosening of the matrix but insufficiently to induce further unfolding might result in freeing these segments. Heating samples of GuHCl-unfolded encapsulated transferrin at temperatures in the range of 60-80°C lead to a progressive blueshift of the fluorescence, from 353 to 340 nm, as expected for increased refolding (Table 1) .
Fluorescence from Apotransferrin and Apo*transferrin. Spectra a and b in Fig. 5B show that the encapsulation of apotransferrin does not result in any substantial perturbation of the corresponding solution-phase spectrum. The peak position of encapsulated holotransferrin, spectrum c, is red-shifted compared with those of the apotransferrin samples. Spectrum d is the spectrum derived from an encapsulated holotransferrin sample at pH 7.5 sample (Protocol 1) that has undergone loss of iron. This encapsulated apo*transferrin sample exhibits a red-shift compared with the encapsulated apotransferrin sample. Spectrum e of GuHCl-unfolded sample e is distinct from that of apo*transferrin.
Discussion
Protocols have been developed for encapsulating proteins in porous TMOS-based sol-gels without denaturation or significant loss of function. Iron-loaded lobes of human transferrin in solution or in crystals are detected only in the closed conformation, whereas iron-free lobes are in the open conformation (7). The present study indicates that encapsulated human holotransferrin and apotransferrin retain their solution equilibrium conformations, and that the sol-gel matrix confers resistance to thermal unfolding.
Specific sol-gel preparative protocols can greatly slow or even stop tertiary and quaternary conformational changes in encapsulated proteins (18-22, 24, 32) . Therefore, it is possible to ''lock in'' an initial protein conformation that resists changes induced by substrate binding or release. Glycerol enhances resistance to conformational change (22, 32) , whereas PEG has the opposite effect (unpublished observations).
Encapsulated transferrin can undergo guanidine-induced unfolding, achieving a state spectroscopically identical to the corresponding solution-phase sample. Addition of glycerol to the encapsulated unfolded sample produces changes consistent with refolding, whereas removal of glycerol results in partial or complete reversal of these changes. Inability to retain glycerol-induced refolding after removal of glycerol suggests that the refolding is incomplete and that the partially refolded protein is less stable than the fully folded species. Moderate heating of encapsulated unfolded transferrin sample produces signs of folding (33) , supporting the suggestion that segments of unfolded protein ''stuck'' within pores of the sol-gel are responsible for the conformational instability of the partially refolded species.
Samples encapsulated as apotransferrin take up iron at a rate that is at least an order of magnitude slower than the rate of corresponding samples encapsulated as holotransferrin and then rendered iron-free. If the sol-gel biases the distribution of conformations toward those associated with the initially encapsulated equilibrium population, then the apotransferrin and apo*transferrin samples will be predominately locked in ''open'' and ''closed'' conformations, respectively. Present results indicate that iron binding is retarded in the open conformation and enhanced in the closed conformation.
In support of this hypothesis, iron uptakes by the apo*transferrin samples depend upon the protocol used to prepare the sol-gel. Incorporation of PEG produces a looser sol-gel that allows a greater degree of conformational relaxation (23) . The PEG containing apo*transferrin sample (A 2 *) shows the slowest uptake of the apo*transferrin samples, as expected if the looser gel permits even partial relaxation toward the equilibrium distribution of open apotransferrin conformations. Analogously, A 1 and A 1 *, respectively, are expected to exhibit extremes in distributions of open and closed conformations, which is consistent with uptake rates for A 1 being the slowest and A 1 * being the fastest of the three sets of encapsulated iron-free transferrins.
Fluorescence data are also consistent with three spectroscopically distinct conformations of transferrin of differing iron uptake rates. As shown in Table 1 , a range of peak positions is associated with different preparations of transferrin. The ''red'' end point of the range (320-354 nm) of accessible peaks for the transferrin samples is achieved for unfolded transferrin at 354 nm. Apotransferrin in either solution phase or encapsulated form yields the peak position (320 nm) that represents the extreme blue-shifted end of observed peaks. Holotransferrin at pH 7.5 in solution and in the sol-gel has a peak position that is red-shifted from that of apotransferrin by 12 nm. Apo*transferrins at pH 7.5 yield peaks dependent on the protocol for encapsulation. The sol-gel of Protocol 1, anticipated to be the most limiting in relaxation of protein conformation, yields the most red-shifted peak position (337 nm) for the pH 7.5 apo*transferrins. The two pH 7.5 PEGcontaining sol-gels yield peak positions for apo*transferrin (A 2 * and A 3 *) that are slightly blue-shifted (330 or 331 nm) with respect to the parent holotransferrin samples and significantly blue-shifted with respect to A 1 *. The A 3 * sample prepared by Protocol 3 contains both PEG and glycerol, and yields an initial peak as red-shifted as the A 1 * sample, but over the course of about 24 h develops a progressive blue shift toward its final position (Ϸ3373330 nm). The apo*transferrin results are consistent with A 1 * having a conformation most closely associated with the initial holotransferrin samples and both A 2 * and A 3 * having conformations that have relaxed partially toward the equilibrium apotransferrin conformation in solution.
The pattern of iron uptake as a function of preparative history supports a model in which the initial step for iron binding requires a transient closed jaw conformation. We suggest that the fastest binding occurs for the closed conformations that have retained the equilibrium conformation of holotransferrin at pH 7.5, with binding slowed as the open conformation associated with solution equilibrium apotransferrin becomes predominant.
Extrapolating these results to the solution phase leads to the hypothesis that the mechanism for iron uptake by transferrin occurs through a transition state in which iron encounters an apotransferrin molecule that has transiently adopted a closed or partially closed conformation. At any instant, apotransferrin is comprised of a distribution of conformational substates that includes both the abundant open form as well as the much less prevalent closed and partially closed forms. Interconversion among the members of the distribution is thermally driven through conformational fluctuations. The rate of iron binding to the transient population of closed apotransferrin is significantly faster than the binding to the more prevalent open jaw forms. In the limit where iron binds only to the closed conformation, the rate at which the apotransferrin population is converted to holotransferrin is controlled by both the rate at which the closed apotransferrin population binds iron and the rate at which the closed form is repopulated through the thermal interconversion process. The possibility that iron initially binds to spectroscopically silent ligands of the open or partially closed conformation and then stabilizes the protein in a conformation with a visible absorption band cannot be excluded, but it is not supported by experimental evidence. Conformational changes in gel-encapsulated proteins are slow, usually requiring hours to days, so that we would expect to find EPR or UV-visible spectroscopic intermediates if iron bound initially to an open conformation. No such intermediates could be detected. Our results favor the hypothesis that a conformational search underlies the binding of iron by transferrin.
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